Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707

Source :: Plus Company Updates. February 13, 2024
Publication Year :: 2024
Abstract: PITTSBURGH: Krystal Biotech, Inc. , a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation for inhaled KB707 for the treatment of [...]

Subjects :: United States. Food and Drug Administration
Medical centers -- Health aspects
Biotechnology -- Health aspects
Biotechnology industry -- Health aspects
General interest
News, opinion and commentary

Tools